AmeriServ Financial Announces the Election of J. Michael Adams, Jr. as Independent Chairman of the Board of Directors

AmeriServ Financial Announces the Election of J. Michael Adams, Jr. as Independent Chairman of the Board of Directors

Also Elects Kim W. Kunkle as Vice Chairman

Thanks Retired Board Members Allan R. Dennison and Sara A. Sargent for Years of Service

JOHNSTOWN, Pa.–(BUSINESS WIRE)–
AmeriServ Financial, Inc. (NASDAQ: ASRV) (“AmeriServ” or the “Company”) today announced that J. Michael Adams, Jr. has been elected non-executive Chairman of the Company’s Board of Directors (the “Board”). In addition, AmeriServ announced that Kim W. Kunkle has been elected non-executive Vice Chairman of the Board. Mr. Adams, who previously held the role of Vice Chairman, succeeds Allan R. Dennison following his recent retirement from the Board.

Mr. Adams commented:

“I want to thank the Board for electing Kim and myself to these important roles at this critical juncture for AmeriServ. There is significant runway for AmeriServ to continue enhancing value for shareholders, customers, employees and the community it serves. As we navigate the current banking sector dislocation in the near-term, we are equally focused on strengthening our operations and seizing new market opportunities over the long-term. I also want to take this moment to convey the full Board’s gratitude to Allan, who helped usher in new initiatives and guide AmeriServ to a strong post-pandemic recovery during his chairmanship. We wish Allan and Sara A. Sargent, who has also retired from the Board, the very best following their years of exceptional service.”

The Board’s decision to elect Messrs. Adams and Kunkle to their new roles reflects its commitment to balancing experience and institutional knowledge with the integration of new members and fresh perspectives. Over the past three years, the Board has added four new independent members as part of its strategic refreshment. The Board intends to continue enhancing AmeriServ’s corporate governance and recruiting new directors with additive skillsets.

Mr. Adams concluded:

“We are extremely proud that AmeriServ is a valuable community institution headquartered in Johnstown, with geographic reach throughout Western Pennsylvania and Western Maryland. This presence is helping us to attract excellent directors as we continue to add new skills and expertise to our boardroom. We recently welcomed two new, highly qualified directors in Richard “Rick” W. Bloomingdale and David J. Hickton. The Board looks forward to working with them to pursue the exciting opportunities for long-term value creation that are ahead.”

J. Michael Adams, Jr. Biography

Mr. Adams is the managing member of Mike Adams & Associates LLC, a Pittsburgh-based consulting firm. He has over three decades of professional experience, including serving as legal counsel to numerous private businesses, public institutions, boards and commissions. Mr. Adams also previously served as chairman of the Board of Directors of the Daily News Publishing Co., a privately held company.

He received a B.S. from Carnegie Mellon University and a J.D. from University of Pittsburgh School of Law.

Kim W. Kunkle Biography

Mr. Kunkle has served since 1984 as the president and CEO of Laurel Holdings, Inc., a closely held private company with wholly owned subsidiaries involved in underground utility construction, plumbing, janitorial services, metal machining, industrial tool distribution, and pipeline rehabilitation. Laurel Holdings employs more than 200 people in western Pennsylvania.

He received a B.A. in management science from Duke University.

About AmeriServ Financial, Inc.

AmeriServ Financial, Inc. is the parent of AmeriServ Financial Bank and AmeriServ Trust and Financial Services Company in Johnstown, Pennsylvania. The Company’s subsidiaries provide full-service banking and wealth management services through 17 community offices in southwestern Pennsylvania and Hagerstown, Maryland. The Company also operates loan production offices in Altoona and Monroeville, Pennsylvania. On March 31, 2023, AmeriServ had total assets of $1.346 billion and a book value of $6.18 per common share. For more information, visit www.ameriserv.com.

Longacre Square Partners

Greg Marose / David Reingold, 646-277-8813

[email protected] / [email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

— At Week 24, 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis (≥2 mm) compared with 11% of patients receiving placebo —

DUBLIN–(BUSINESS WIRE)–
Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive topline results from its randomized, double-masked, placebo-controlled Phase 3 clinical trial evaluating TEPEZZA for the treatment of TED in Japanese patients with higher levels of disease activity, as measured by clinical activity score (CAS). TED is a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness and swelling.1

“The positive topline results from this trial are important because there are no approved medicines in Japan for Thyroid Eye Disease, resulting in a significant unmet need for patients who are struggling with the physical symptoms of the disease as well as the emotional and social burden that is associated with it,” said Yuji Hiromatsu, M.D., professor emeritus, Kurume University Medical Center and co-coordinating trial investigator. “Currently, the only treatment options in Japan are steroids and multiple invasive surgeries. TEPEZZA would offer patients a non-surgical option that not only treats the symptoms, such as proptosis and diplopia, but targets the underlying mechanism of the disease.”

Topline data demonstrated that the primary endpoint was met. At Week 24, 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis (≥2 mm) compared with placebo (11%) (p<0.0001). The safety profile is consistent with what was observed in previous clinical trials of TEPEZZA. Additional data from the trial will be presented at a medical congress and published in a peer-reviewed medical journal.

“We are thrilled with the results of this trial, and we look forward to working with local investigators and regulators to bring this innovative therapy to patients in Japan who are suffering from Thyroid Eye Disease,” said Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, Horizon. “The participation by those living with Thyroid Eye Disease in this clinical trial and the trial investigators was integral in helping us reach this significant milestone.”

A second Phase 3 clinical trial is ongoing in Japan evaluating TEPEZZA for the treatment of adults with chronic TED and low CAS. This trial includes patients with an initial diagnosis of TED between two to 10 years prior to the study and low levels of disease activity.

TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) in January 2020 as the first and only medicine for TED. TEPEZZA has not been approved for commercial use in Japan. There are no medicines approved for the treatment of TED in Japan.

Trial Design

The OPTIC-J trial is a randomized, double-masked, placebo-controlled, parallel-group, multicenter study evaluating the efficacy, tolerability and safety of TEPEZZA in the treatment of patients with moderate-to-severe active TED in Japan. The trial methodology is based on the OPTIC Phase 3 trial conducted in the United States and Europe. Adult participants who met the eligibility criteria were randomized in a 1:1 ratio to receive TEPEZZA (n=27) or placebo (n=27) once every three weeks for a total of eight infusions (10 mg/kg for the first infusion and 20 mg/kg for the remaining seven infusions). All patients were dosed as randomized, and all patients completed the Week 24 assessment.

The primary efficacy endpoint is proptosis response rate at Week 24, measured by the percentage of participants with at least a 2 mm reduction in proptosis from baseline in the study eye, without deterioration in the fellow eye (≥2 mm increase). Study participants who complete the treatment period and are proptosis non-responders at Week 24 may choose to enter an open-label extension period to receive an additional eight infusions of TEPEZZA.

The trial was designed in consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). More information about the trial is available on the Japan Registry of Clinical Trials website (trial ID number jRCT2031210453).

About Thyroid Eye Disease (TED)

TED is a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease.1 It often occurs in people living with Graves’ disease, but is a distinct disease that is caused by autoantibodies activating an insulin-like growth factor-1 receptor (IGF-1R)-mediated signaling complex on cells within the retro-orbital space.2,3 This leads to a cascade of negative effects, which may cause long-term, irreversible damage, including blindness.4,5 Early signs and symptoms of TED may include dry eyes and grittiness; redness, swelling and excessive tearing; eyelid retraction; proptosis; pressure and/or pain behind the eyes; and diplopia.

About TEPEZZA

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, and menstrual disorders.

Please see Full Prescribing Information or visit TEPEZZAhcp.comfor more information.

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the potential benefits of TEPEZZA; the potential approval and commercial availability of TEPEZZA in Japan; the design of clinical trials and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks regarding whether additional clinical trial results or data analyses will be consistent with preliminary results or results of other trials or Horizon’s expectations, the risks associated with regulatory approvals and adoption of novel medicines, as well as those described in Horizon’s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

References

  1. Barrio-Barrio J, et al. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. Journal of Ophthalmopathy. 2015;2015:249125.

  2. Weightman DR, et al. Autoantibodies to IGF-1 Binding Sites in Thyroid Associated Ophthalmopathy. Autoimmunity. 1993;16(4):251–257.

  3. Pritchard J, et al. Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves’ Disease Is Mediated Through the Insulin-Like Growth Factor 1 Receptor Pathway. J Immunol. 2003;170:6348-6354.

  4. McKeag D, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007;91:455-458.

  5. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves’ Orbitopathy [published online ahead of print]. Eur J Endocrinol. 2021 Jul 1:EJE-21-0479.R1. doi: 10.1530/EJE-21-0479.

 

Investor Relations:

Tina Ventura

Senior Vice President, Chief Investor Relations Officer

[email protected]

U.S. Media:

Rachel Vann

Senior Director, Product Communications

[email protected]

Ireland Media:

Eimear Rigby

Associate Director, Corporate Communications

[email protected]

KEYWORDS: Europe Ireland United States North America New York

INDUSTRY KEYWORDS: Health Clinical Trials Research Science Pharmaceutical Optical Biotechnology

MEDIA:

Logo
Logo

Bowman Expands Southwest Gas On-Call Engagement into Southern Nevada

Bowman Expands Southwest Gas On-Call Engagement into Southern Nevada

RESTON, Va.–(BUSINESS WIRE)–
Bowman Consulting Group Ltd. (“Bowman” or the “Company”) (NASDAQ: BWMN) announced that the Company has been selected by Southwest Gas Corporation’s Southern Nevada division for a new multi-year, on-call engineering and land survey services contract. This is in addition to recent extensions of the firm’s similar Southern Arizona contracts. Bowman’s teams will provide engineering, design and planning, and survey services including right-of-way, property line stakeout, high-pressure line cut sheets and legal exhibits, along with other related services, as required.

The Southern Nevada contract is the first Southwest Gas engagement for Bowman in the state. Since 2014, Bowman has delivered survey, civil engineering, design, and planning services to Southwest Gas’ Arizona Central and Southern divisions. During that time, Bowman established a relationship built on responsiveness and process improvement that has enabled teaming on hundreds of projects per year and elevated Southwest Gas to one of the Company’s largest clients.

Southwest Gas Corporation provides natural gas service to more than 2 million customers throughout Arizona, Nevada, and portions of California. The company is dedicated to investing in sustainable and responsible business practices that protect the environment, preserve natural resources and safeguard customers and employees.

“Southwest Gas is a leading utility and trusted services provider to its customers,” said Gary Bowman, chairman and CEO of Bowman. “We are focused on supporting utility system operators contending with various pipe types and extreme weather events by providing services oriented toward facility fortification, resilience assurance, and infrastructure modernization. For nearly a decade, we have deployed highly skilled professionals to work side-by-side with Southwest Gas field teams. We are pleased to expand our partnership with Southwest Gas into Nevada as one of their trusted utility services partners.”

About Bowman Consulting Group Ltd. (Bowman): Headquartered in Reston, Virginia, Bowman is an engineering services firm delivering infrastructure solutions to customers who own, develop, and maintain the built environment. With approximately 1,700 employees in more than 75 offices in the United States, Bowman provides a variety of planning, engineering, geospatial, construction management, commissioning, environmental consulting, land procurement and other technical services to customers operating in a diverse set of regulated end markets. Bowman trades on the Nasdaq under the symbol BWMN. For more information, visit bowman.com or investors.bowman.com.

Investor Relations Contacts:

Bruce Labovitz, 703.787.3403

[email protected]

Larry Clark, 310.622.8223

[email protected]

General Media Contact:

Jennifer Kamienski, 201.519.4536

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Professional Services Engineering Oil/Gas Manufacturing Energy Consulting

MEDIA:

Logo
Logo

Redfin Report: The Spring 2023 Homebuying Season Never Happened

Redfin Report: The Spring 2023 Homebuying Season Never Happened

Near-7% mortgage rates are preventing both would-be homebuyers and would-be sellers from entering the market. Construction of new single-family homes is near its highest level in almost two decades, providing some hope for an uptick in inventory by next year.

SEATTLE–(BUSINESS WIRE)–
(NASDAQ: RDFN) — As spring turns into summer, it’s official: The traditionally hot spring homebuying season didn’t come to fruition in 2023. That’s according to a new report from Redfin (redfin.com), the technology-powered real estate brokerage. This year, instead of the calendar determining the homebuying season, the Federal Reserve is dictating when people buy and sell. And so far, the Fed’s actions are suggesting they wait.

Pending home sales fell 16% from a year earlier during the four weeks ending June 18. But even though sales are relatively tepid, Redfin’s Homebuyer Demand Index—a measure of requests for tours and other early-stage buying services from Redfin agents—is up 11% year over year. Additionally, there are more house hunters than there are homes hitting the market. New listings of homes for sale are down 24% from a year ago, and the total number of homes for sale is down 8%, the biggest drop in over a year.

Elevated mortgage rates are responsible for the drops on both the demand and supply sides. With average rates sitting above 6% all spring, pushing the typical U.S. monthly housing payment up near record highs, many would-be buyers are sitting on the sidelines, waiting for rates to come down. And the buyers who are out there are having a hard time finding listings, with many prospective sellers staying put, hanging onto their relatively low rates: Nearly all homeowners with a mortgage have a rate below 6%.

The continuing inventory shortage is bolstering home prices. The median U.S. home-sale price dropped just 1% year over year this week, the smallest decline in more than three months. On a local level, prices have started leveling off: They fell in 25 of the 50 most populous metros, compared with 29 a month ago. In San Jose, CA, for instance, the median sale price is up roughly 2% year over year, marking the first increase after eight straight months of declines.

“There are two things that would jumpstart the housing market: A big drop in mortgage rates and/or a big surge of new listings,” said Redfin Deputy Chief Economist Taylor Marr. “Neither of those things happened this spring; instead, rates rose and new listings dropped to record lows. And with one or two more interest-rate hikes expected this year, mortgage rates are likely to remain elevated at least through the summer, continuing to limit both demand and supply.”

“But even though there wasn’t much of a spring homebuying season this year, there was a spring building season,” Marr continued. “That means there’s hope for more listings somewhat soon, with homebuilders working to fill the inventory bucket. Builders broke ground on more single-family homes in May than almost any month in nearly two decades, which could expand buyers’ options by the end of the year.”

Leading indicators of homebuying activity:

  • The daily average 30-year fixed mortgage rate was 6.9% on June 21, down from a half-year high of 7.14% a month earlier. For the week ending June 15, the average 30-year fixed mortgage rate was 6.69%, down slightly from 6.71% the week before but still close to the highest rate since November.

  • Mortgage-purchase applications during the week ending June 16 rose 2% from a week earlier, seasonally adjusted, marking the second straight week of increases. Purchase applications were down 32% from a year earlier.

  • The seasonally adjusted Redfin Homebuyer Demand Index was down slightly from a week earlier during the week ending June 18. It was up 11% from a year earlier, the fourth consecutive annual increase. Demand was dropping at this time in 2022 as mortgage rates rose.

  • Google searches for “homes for sale” were up 13% from a month earlier during the week ending June 17, and down about 11% from a year earlier.

  • Touring activity as of June 18 was up 14% from the start of the year, compared with a 4% decrease at the same time last year, according to home tour technology company ShowingTime. Tours increased slowly during this time last year as mortgage rates shot up.

Key housing market takeaways for 400+ U.S. metro areas:

Unless otherwise noted, this data covers the four-week period ending June 18. Redfin’s weekly housing market data goes back through 2015. For bullets that include metro-level breakdowns, Redfin analyzed the 50 most populous U.S. metros. Select metros may be excluded from time to time to ensure data accuracy.

  • The median home sale price was $382,861, down 1% from a year earlier, the smallest decline in more than three months. Price declines have been shrinking for the last two months.

  • Home-sale prices declined in 25 metros, with the biggest drops in Austin, TX (-11% YoY), Las Vegas (-9.1%), Detroit (-8%), Los Angeles (-7.1%) and Phoenix (-6.8%).

  • Sale prices increased most in Fort Lauderdale, FL (8.6%), Miami (8.5%), Providence, RI (5.5%), Milwaukee (5.2%) and Virginia Beach, VA (5.1%).

  • The median asking price of newly listed homes was $397,225 up 0.3% from a year earlier.

  • The monthly mortgage payment on the median-asking-price home was $2,628 at a 6.69% mortgage rate, the average for the week ending June 15. That’s down slightly from the record high hit three weeks earlier, but up 8% ($190) from a year earlier.

  • Pending home sales were down 15.7% year over year, continuing a 13-month streak of double-digit declines.

  • Pending home sales fell in all metros Redfin analyzed. They declined most in Milwaukee (-28% YoY), Providence (-26.3%), Seattle (-25.6%), Portland, OR (-24.8%) and San Diego (-23.4%).

  • New listings of homes for sale fell 24% year over year, roughly on par with the declines over the last two months.

  • New listings declined in all metros Redfin analyzed. They fell most in Las Vegas (-42.3% YoY), Phoenix (-42%), Oakland, CA (-38.8%), Seattle (-37.4%) and San Diego (-36.2%).

  • Active listings (the number of homes listed for sale at any point during the period) dropped 8.1% from a year earlier, the biggest drop in over a year. Active listings were up slightly from a month earlier; typically, they post month-over-month increases at this time of year.

  • Months of supply—a measure of the balance between supply and demand, calculated by the number of months it would take for the current inventory to sell at the current sales pace—was 2.5 months, the lowest level in nearly a year. Four to five months of supply is considered balanced, with a lower number indicating seller’s market conditions.

  • 32.9% of homes that went under contract had an accepted offer within the first two weeks on the market, down from 36% a year earlier.

  • Homes that sold were on the market for a median of 27 days, the shortest span since August. That’s up from a near-record low of 19 days a year earlier.

  • 36.3% of homes sold above their final list price. That’s the highest share since last August but is down from 53% a year earlier.

  • On average, 5.3% of homes for sale each week had a price drop, up from 4.8% a year earlier.

  • The average sale-to-list price ratio, which measures how close homes are selling to their final asking prices, was 100%. That means homes are selling for exactly their asking price, on average, for the first time in 10 months. That’s down from 102.2% a year earlier.

To view the full report, including charts, please visit: https://www.redfin.com/news/housing-market-update-spring-homebuying-season-never-happened

About Redfin

Redfin (www.redfin.com) is a technology-powered real estate company. We help people find a place to live with brokerage, rentals, lending, title insurance, and renovations services. We sell homes for more money and charge half the fee. We also run the country’s #1 real estate brokerage site. Our home-buying customers see homes first with on-demand tours, and our lending and title services help them close quickly. Customers selling a home in certain markets can have our renovations crew fix up their home to sell for top dollar. Our rentals business empowers millions nationwide to find apartments and houses for rent. Customers who buy and sell with Redfin pay a 1% listing fee, subject to minimums, less than half of what brokerages commonly charge. Since launching in 2006, we’ve saved customers more than $1.5 billion in commissions. We serve more than 100 markets across the U.S. and Canada and employ over 5,000 people.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

Redfin Journalist Services:

Kenneth Applewhaite, 206-588-6863

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Commercial Building & Real Estate Technology Construction & Property Software Internet Retail Data Management Residential Building & Real Estate Online Retail

MEDIA:

Logo
Logo

Abacus Life to Participate in Fireside Chat with IPO Edge and The Palm Beach Hedge Fund Association Friday, June 23 at 9:00am ET

Abacus Life to Participate in Fireside Chat with IPO Edge and The Palm Beach Hedge Fund Association Friday, June 23 at 9:00am ET

ORLANDO, Fla. & BOCA RATON, Fla.–(BUSINESS WIRE)–
Abacus Settlements, LLC (d/b/a Abacus Life) and Longevity Market Assets, LLC (together “Abacus” or the “Company”), a leading buyer of life insurance policies and vertically integrated alternative asset manager specializing in specialty insurance products, will participate in a virtual fireside chat with The Palm Beach Hedge Fund Association and IPO Edge Friday, June 23, 2023 at 9:00am ET.

The live event will feature Abacus President and CEO, Jay Jackson and will be moderated by IPO Edge Editor-in-Chief John Jannarone who will discuss:

  • Abacus’ business combination with East Resources Acquisition Company (NASDAQ: ERES);

  • Current ownership structure and growth story;

  • Abacus’ business model;

  • Scale of the business and growth projections;

  • Expectations for capital raises or new investors in the next couple of years;

  • Abacus’ acquisition strategy whether core or opportunistic;

  • Recent or forward-looking growth metrics;

The hour-long video session will include a Q&A with the audience. Interested parties can submit their questions ahead of the event via email to [email protected].

To register for the event, please CLICK HERE.

Abacus Life has entered into a definitive merger agreement with East Resources Acquisition Corporation (NASDAQ: ERES) (“ERES”), a special purpose acquisition company, that will result in Abacus becoming a publicly listed company. Upon closing of the transaction, which is expected to close on June 30, 2023, the combined company will be named Abacus Life, Inc. and is expected to remain listed on Nasdaq under the new ticker symbol “ABAL.”

About Abacus

Abacus is a leading vertically integrated alternative asset manager specializing in life insurance products. Since 2004, the company has purchased life insurance policies from consumers seeking liquidity and has actively managed those policies over time (via trading, holding, and/or servicing). With over $2.9 billion in face value of policies purchased, Abacus has helped thousands of clients maximize the value of life insurance.

Over the past 18 years, the company has built an institutionalized origination and portfolio management process that is supported by a 83-person team, long-term relationships with 78 institutional partners and 30,000 financial advisors, and the ability to operate in 49 states. The company has serviced approximately $950 million in policies and has managed assets for large asset managers and third-party investment funds.

Abacus’ leadership team averages 20+ years of experience and have been innovators since the life settlements industry’s inception in the mid-90s.

The company is a proud member of the Life Insurance Settlements Association (LISA) and complies with HIPAA and privacy laws to maintain and protect confidentiality of financial, health, and medical information. Abacus is also proud to be a BBB Accredited Business with an A+ rating.

www.Abacuslife.com

About East Resources Acquisition Company

East Resources Acquisition Company, led by Terrence (Terry) M. Pegula, is a blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses in North America.

Forward-Looking Statements

This communication contains certain forward-looking statements within the meaning of the federal securities laws with respect to the transaction, including statements regarding the anticipated benefits of the transaction, the anticipated timing of the transaction, the future financial condition and performance of Abacus and expected financial impacts of the transaction (including future revenue and pro forma enterprise value) and the platform and markets and expected future growth and market opportunities of Abacus. These forward-looking statements generally are identified by the words “believe,” “predict,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “scales,” “representative of,” “valuation,” “potential,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negatives of these terms or variations of them. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are inherently subject to risks and uncertainties. These forward‐looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are beyond ERES’s or Abacus’s control, are difficult or impossible to predict and may differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ERES’s securities, (ii) the risk that the transaction may not be completed by ERES’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by ERES, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the requisite approvals of ERES’s stockholders and Abacus’s owners, the satisfaction of the minimum aggregate transaction proceeds amount following any redemptions by ERES’s public stockholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement relating to the transaction, (vi) the effect of the announcement or pendency of the transaction on Abacus’s business or employee relationships, operating results and business generally, (vii) the risk that the transaction disrupts current plans and operations of Abacus, (viii) the risk of difficulties in retaining employees of Abacus as a result of the transaction, (ix) the outcome of any legal proceedings that may be instituted against Abacus or against ERES related to the merger agreement or the transaction, (x) the ability to maintain the listing of ERES’s securities on a national securities exchange, (xi) changes in the competitive industries in which Abacus operate, variations in operating performance across competitors, changes in laws and regulations affecting Abacus’s business and changes in the combined capital structure, (xii) the ability to implement business plans, forecasts, and other expectations after the completion of the transaction, and the ability to identify and realize additional opportunities, (xiii) risks related to the uncertainty of Abacus’s projected financial information, (xiv) current and future conditions in the global economy, including as a result of the impact of the COVID-19 pandemic, (xv) the risk that demand for Abacus’s life settlement and related offerings does not grow as expected, (xvi) the ability of Abacus to retain existing customers and attract new customers, (xvii) the potential inability of Abacus to manage growth effectively, (xviii) the potential inability of Abacus to grow its market share of the life settlement industry or to achieve efficiencies regarding its operating model or other costs, (xix) negative trends in the life settlement industry impacting the value of life settlements, including increases to the premium costs of life insurance policies, increased longevity of insureds, and errors in the methodology and assumptions of life expectancy reports, (xx) legal challenges by insurers relating to the validity of the origination or assignment of certain life settlements, (xxi) the enforceability of Abacus’s intellectual property rights, including its trademarks and trade secrets, and the potential infringement on the intellectual property rights of others, (xxii) Abacus’s dependence on senior management and other key employees, (xxiii) the risk of downturns and a changing regulatory landscape in the industry in which Abacus operates, and (xxiv) costs related to the transaction and the failure to realize anticipated benefits of the transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions. The foregoing list of factors is not exhaustive.

Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should carefully consider the foregoing factors and the other risks and uncertainties which will be more fully described in the “Risk Factors” section of the proxy statement discussed below and other documents filed by ERES from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers of this communication are cautioned not to put undue reliance on forward-looking statements, and Abacus and ERES assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Abacus nor ERES gives any assurance that any of Abacus or ERES, or the combined company, will achieve expectations.

Additional Information About the Proposed Transaction and Where to Find It

This communication relates to the proposed transaction between ERES and Abacus. In connection with the proposed transaction, ERES has filed with the SEC a preliminary proxy statement on Schedule 14A (the “proxy statement”). ERES will also file other documents regarding the transaction with the SEC. Before making any voting decision, investors, security holders and other interested persons of ERES and Abacus are urged to read the proxy statement (including all amendments and supplements thereto), which is currently available, and all other relevant documents filed or that will be filed with the SEC in connection with the transaction as they become available because they will contain important information about the transaction. Investors, security holders and other interested persons will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by ERES through the website maintained by the SEC at www.sec.gov. The documents filed by ERES with the SEC also may be obtained free of charge upon written request to ERES at 7777 NW Beacon Square Boulevard, Boca Raton, Florida.

Participants in the Solicitation

ERES, Abacus and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from ERES stockholders in connection with the transaction. A list of the names of such directors and executive officers and information regarding their interests in the transaction are or will be contained in the proxy statement. You can find more information about ERES’s directors and executive officers in ERES’s Annual Report on Form 10-K for the year ended December 31, 2021, which ERES filed with the SEC on June 22, 2022. You may obtain free copies of these documents as described in the preceding paragraph.

No Offer or Solicitation

This communication does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, sale, or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act, or an exemption therefrom.

East Resources Acquisition Company

Investor Contact: Kelly Seward

[email protected]

Abacus Life Investor Relations

[email protected]

Abacus Life Public Relations

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Professional Services Other Professional Services Insurance Finance Asset Management Banking

MEDIA:

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK–(BUSINESS WIRE)–
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on June 16, 2023, the company granted (i) non-statutory stock options to purchase 14,325 shares of the company’s common stock to 11 newly hired employees and (ii) restricted stock units (RSUs) with respect to 11,138 shares of the company’s common stock to 11 newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock options have an exercise price of $45.98 per share, equal to the closing price of Schrödinger’s common stock on June 16, 2023. The stock options have a ten-year term and vest over four years, with 25 percent of the shares underlying the option vesting when the employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee’s completion of each additional month of service over the 36-month period following the first anniversary of the employment start date.

The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee’s completion of each additional year of service over the three-year period following the first anniversary of the employment start date.

The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company’s 2021 Inducement Equity Incentive Plan.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The computational platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.

Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.

Investors:

Jaren Madden

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Biotechnology Science Health Research

MEDIA:

Logo
Logo

BigCommerce Named a Major Contender in 2023 Digital Commerce Platform PEAK Matrix® by Everest Group

BigCommerce Named a Major Contender in 2023 Digital Commerce Platform PEAK Matrix® by Everest Group

Open SaaS platform recognized for flexibility and agility to meet evolving enterprise expectations as the market shifts toward more composable and modular architectures

AUSTIN, Texas–(BUSINESS WIRE)–BigCommerce (Nasdaq: BIGC), a leading Open SaaS ecommerce platform for fast-growing and established B2C and B2B brands, today announced it has been named a Major Contender in Everest Group’s 2023 Digital Commerce Platform PEAK Matrix®. BigCommerce scored second to highest among competitors in both Visibility and Capability.

“Given the rapid ecommerce market shifts and expectations, enterprises need architectures best equipped for agility and composable commerce is becoming the preferred model. Everest Group’s recognition reflects BigCommerce’s ability to provide the flexibility and deliver on these needs in today’s fast-paced ecommerce space,” said Meghan Stabler, senior vice president at BigCommerce. “We continue to invest in our capabilities to best serve our merchants all over the world, especially against an ever-changing macroeconomic backdrop, that ensures their staying power. BigCommerce’s high placement in the Major Contender quadrant proves this.”

According to Everest Group, the pandemic caused a massive spike in the demand for digital commerce, especially from small and mid-size enterprises that revamped their online presence strategy. The post-pandemic world continues to experience a rise in this demand. As customer touchpoints increase and customer purchase journeys become more complex, digital commerce platform providers are evolving their offerings to meet evolving enterprise expectations.

In this report, Everest Group assessed 21 technology providers across all industries and geographies. The study is based on Everest Group’s annual RFI process for the calendar year 2022, interactions with leading technology providers, client reference checks and an ongoing analysis of the digital commerce market.

To learn more about BigCommerce’s enterprise ecommerce solutions, click here.

About BigCommerce

BigCommerce (Nasdaq: BIGC) is a leading open software-as-a-service (SaaS) ecommerce platform that empowers merchants of all sizes to build, innovate and grow their businesses online. BigCommerce provides merchants sophisticated enterprise-grade functionality, customization and performance with simplicity and ease-of-use. Tens of thousands of B2C and B2B companies across 150 countries and numerous industries use BigCommerce to create beautiful, engaging online stores, including Ben & Jerry’s, Molton Brown, S.C. Johnson, Skullcandy, Solo Stove, Ted Baker and Vodafone. Headquartered in Austin, BigCommerce has offices in London, Kyiv, San Francisco, and Sydney. For more information, please visit www.bigcommerce.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

BigCommerce® is a registered trademark of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owners.

Dana Marruffo

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Online Retail Retail Technology Software Networks Internet

MEDIA:

Logo
Logo

Soluna Holdings’ CEO John Belizaire Addresses Shareholders in Open Letter, Publishes Earnings Power Highlighting Path to Profitability

Soluna Holdings’ CEO John Belizaire Addresses Shareholders in Open Letter, Publishes Earnings Power Highlighting Path to Profitability

ALBANY, N.Y.–(BUSINESS WIRE)–
Soluna Holdings, Inc. (“SHI” or the “Company”), (NASDAQ: SLNH), the parent company of Soluna Computing, Inc. (“SCI”), a developer of green data centers for Bitcoin mining and other intensive computing applications, announced an open letter to shareholders from Soluna Holdings CEO, John Beliziare.

A longer version of the letter as well as an earnings power presentation can be found on Soluna’s website.

Open Letter to Shareholders from John Belizaire, CEO of Soluna Holdings, Inc.

Dear Shareholders,

As the new CEO of Soluna Holdings, Inc., I want to share my reflections on the past year and outline our path ahead, and I want to acknowledge the challenges we faced and commend the resilience and adaptability of our organization.

In 2022, we had ambitious plans to energize over 100 MW of new data centers powered by renewable energy but changes in the business environment got in the way. Key players in the crypto ecosystem collapsed. The war in Ukraine negatively impacted our financing options and power costs.

We adapted. We changed our strategy and continued pursuing our goals. We secured project-level financing with Spring Lane Capital and implemented cost-cutting measures, including staff layoffs, while maintaining our focus on Project Dorothy, our flagship project in Texas.

Looking ahead to 2023, our primary focus is on energizing and commercializing Project Dorothy. We received final approval from the Texas regulator, ERCOT, and closed a transaction with Spring Lane Capital to provide the liquidity to complete the 25 MW Project Dorothy 1A. We signed a Joint Venture agreement with Navitas Global, a significant step towards building a 25 MW proprietary mining business at Project Dorothy 1B. Project Sophie in Kentucky secured a 25 MW hosting agreement, which is expected to enhance profitability and serve as the core business model as we begin plans for Project Dorothy 2, which holds great potential for capital-efficient growth.

We are a leading curtailment solutions provider with an expertise in renewable energy and a strong reputation for solving the industry’s biggest challenge, wasted energy. Our behind-the-meter energy costs are among the best in the industry, resulting in solid returns on invested capital. Our pipeline of behind-the-meter projects exceeds 700 MW, and even a fraction of this pipeline has the potential to drive substantial growth and profitability. All of which positions us to achieve positive cash flow from operations in the second half of 2023.

Our proprietary modular design data centers combined with our proprietary MaestroOS(™), enable us to optimize operations, generate strong cash flows and are architected to generate a two-year return of capital invested.

I firmly believe in our mission of making renewable energy a superpower using computing as a catalyst. The passing of the Inflation Reduction Act of 2022 represents a significant opportunity in the renewable energy space, with more projects being built around the grid and congestion becoming a larger issue.

Bitcoin’s prominence in the crypto space and its increasing need for secure solutions make it a perfect fit for our curtailed energy approach, and the rise of AI presents further growth and diversification opportunities for our company.

I extend my deepest gratitude to all of you for your continued support of Soluna and our long-term mission. We are committed to executing our plans and generating value for our shareholders.

Sincerely,

John Belizaire

CEO

Soluna Holdings, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Soluna Holdings, Inc. may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Soluna’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, further information regarding which is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of the press release, and Soluna Holdings, Inc. undertakes no duty to update such information, except as required under applicable law.

About Soluna Holdings, Inc (SLNH)

Soluna Holdings, Inc. is the leading developer of green data centers that convert excess renewable energy into global computing resources. Soluna builds modular, scalable data centers for computing intensive, batchable applications such as Bitcoin mining, AI, and machine learning. Soluna provides a cost-effective alternative to battery storage or transmission lines. Soluna uses technology and intentional design to solve complex, real-world challenges. Up to 30% of the power of renewable energy projects can go to waste. Soluna’s data centers enable clean electricity asset owners to ‘Sell. Every. Megawatt.’

Sam Sova

Founder and CEO

SOVA

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Other Energy Utilities Oil/Gas Coal Alternative Energy Security Energy Nuclear Telecommunications Software Networks Internet Environment Hardware Electronic Design Automation Data Management

MEDIA:

Logo
Logo

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its voting common stock and 7,312,500 shares of its non-voting common stock, in each case at a price to the public of $8.00 per share. In addition, IGM has granted the underwriters a 30-day option to purchase up to an additional 1,589,673 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the public offering will be sold by IGM. The public offering is expected to close on or about June 26, 2023, subject to satisfaction of customary closing conditions.

Concurrent with the public offering, IGM intends to sell, subject to the consummation of the public offering and other customary conditions, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), 2,812,500 shares of non-voting common stock to certain institutional and other accredited investors affiliated with or managed by Redmile Group, LLC at a sale price equal to $8.00 per share. However, the consummation of the public offering is not contingent on the consummation of this concurrent private placement.

IGM expects to receive total gross proceeds of approximately $107.3 million from the public offering and the concurrent private placement, before deducting the underwriting discounts and commissions and estimated offering expenses payable by IGM in connection with the public offering and the concurrent private placement.

BofA Securities, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the public offering.

The securities in the public offering will be offered by IGM pursuant to a Registration Statement on Form S-3, filed with the Securities and Exchange Commission (SEC) on November 3, 2022 and declared effective on November 14, 2022. A final prospectus supplement and accompanying prospectus relating to the public offering will be filed with the SEC and may be accessed for free through the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained from: BofA Securities, Attention: Prospectus Department, NC1-0220-02-24, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, or via email: [email protected]; Jefferies LLC, Attention: Equity Syndicate Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attn: Syndicate, or by phone at (415) 364-2720, or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

The shares of non-voting common stock to be sold in the concurrent private placement have not been registered under the Securities Act or under any state securities laws and, unless so registered may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About IGM Biosciences, Inc.

IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases and infectious diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets.

IGM Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements are not based on historical fact and include, but are not limited to, the expected closing of the public offering and concurrent private placement. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such statements. These risks and uncertainties include, but are not limited to, the final terms of the public offering and the concurrent private placement, the satisfaction of customary closing conditions, prevailing market conditions and the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties, and other important factors, any of which could cause IGM’s actual results to differ from those contained in the forward-looking statements, can be found under the heading “Risk Factors” in IGM’s reports filed with the SEC, in the preliminary prospectus supplement and accompanying prospectus relating to the public offering. IGM assumes no duty or obligation to update or revise any forward-looking statements for any reason.

IGM Biosciences Contact:

Argot Partners
David Pitts
212-600-1902
[email protected]



Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes

HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced that it is set to join the Russell 2000® and Russell 3000 Indexes, according to preliminary membership information posted to the FTSE Russell website. The addition is expected to become effective at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

Jim Green, Harvard Bioscience Chairman and CEO said, “We are pleased that Harvard Bioscience is being added to the Russell 2000 and 3000 Indexes. This addition complements our role as a trusted partner of the world’s leading academic research institutions, contract research organizations, and pharmaceutical and bio-tech companies in the discovery, production, and safety and regulatory compliance of tomorrow’s life-saving therapies.”

Green continued, “In addition to supporting the needs of our customers and the broader healthcare community, we remain focused on our fiscal priorities of driving sustainable, profitable growth, improved operating discipline, and reducing our debt. We believe our inclusion in the indexes will improve visibility and trading liquidity, exposing us to new institutional investors.”

The Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28, ranking them by total market capitalization, including both the Russell 3000 and Russell Microcap Indexes.

Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.1 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell indexes and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $20.1 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future revenues, earnings, cash position, growth, operational performance, and the strength of the Company’s market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Investor Inquiries:

Harvard Bioscience, Inc.
Investor Relations
[email protected]
(508) 893-3120